Today, the University of Oxford published preliminary results of a phase 1/2 trial of a vaccine they developed, the study suggests that the vaccine induces an immune response in addition to being safe.

 

The trial involved 1,077 people in the age range of 18-55 years, with no history of covid-19, and has been conducted at five hospitals in the UK, beginning in late April and continuing through May. Participants were given either covid-19 or meningococcal conjugate vaccine as a control group.

 

Andrew Pollard, lead author of the study, said in a statement that, “this vaccine is intended to induce both, so it can attack the virus when it is circulating in the body, as well as attack infected cells. He explained that the immune system is expected to remember the virus so the vaccine will protect people for a long time.

 

He also stressed that, “more research is needed to confirm that the vaccine effectively protects against SARS-CoV-2 infection and how long any protection lasts.

 

Source: CNN en Español